A citation-based method for searching scientific literature

Delphine Tardivon, Mateusz Antoszewski, Nadine Zangger, Marianne Nkosi, Jessica Sordet-Dessimoz, Rudi Hendriks, Ute Koch, Freddy Radtke. Blood 2021
Times Cited: 3







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Yunhang Guo, Ye Liu, Nan Hu, Desheng Yu, Changyou Zhou, Gongyin Shi, Bo Zhang, Min Wei, Junhua Liu, Lusong Luo,[...]. J Med Chem 2019
114
33

Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain.
T Li, S Tsukada, A Satterthwaite, M H Havlik, H Park, K Takatsu, O N Witte. Immunity 1995
150
33

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Steven P Treon, Lian Xu, Guang Yang, Yangsheng Zhou, Xia Liu, Yang Cao, Patricia Sheehy, Robert J Manning, Christopher J Patterson, Christina Tripsas,[...]. N Engl J Med 2012
788
33

RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
Daigen Xu, Yong Kim, Jennifer Postelnek, Minh Diem Vu, Dong-Qing Hu, Cheng Liao, Mike Bradshaw, Jonathan Hsu, Jun Zhang, Achal Pashine,[...]. J Pharmacol Exp Ther 2012
108
33

Agammaglobulinemia.
O C BRUTON. Pediatrics 1952
33

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
H Yesid Estupiñán, Qing Wang, Anna Berglöf, Gerard C P Schaafsma, Yuye Shi, Litao Zhou, Dara K Mohammad, Liang Yu, Mauno Vihinen, Rula Zain,[...]. Leukemia 2021
12
33

Targeting BTK in CLL: Beyond Ibrutinib.
David A Bond, Jennifer A Woyach. Curr Hematol Malig Rep 2019
66
33

BTKbase: the mutation database for X-linked agammaglobulinemia.
Jouni Väliaho, C I Edvard Smith, Mauno Vihinen. Hum Mutat 2006
126
33

Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
Jiakuo Liu, Chengjuan Chen, Dongmei Wang, Jie Zhang, Tiantai Zhang. Eur J Med Chem 2021
14
33

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Lee A Honigberg, Ashley M Smith, Mint Sirisawad, Erik Verner, David Loury, Betty Chang, Shyr Li, Zhengying Pan, Douglas H Thamm, Richard A Miller,[...]. Proc Natl Acad Sci U S A 2010
33

Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study.
Anna Berteotti, Federica Vacondio, Alessio Lodola, Michele Bassi, Claudia Silva, Marco Mor, Andrea Cavalli. ACS Med Chem Lett 2014
39
33

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
Adam R Johnson, Pawan Bir Kohli, Arna Katewa, Emily Gogol, Lisa D Belmont, Regina Choy, Elicia Penuel, Luciana Burton, Charles Eigenbrot, Christine Yu,[...]. ACS Chem Biol 2016
77
33




Agammaglobulinemia: causative mutations and their implications for novel therapies.
Anna Berglöf, Janne J Turunen, Olof Gissberg, Burcu Bestas, K Emelie M Blomberg, C I Edvard Smith. Expert Rev Clin Immunol 2013
17
33

Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia.
Tom A Mulder, Lucía Peña-Pérez, Anna Berglöf, Stephan Meinke, H Yesid Estupiñán, Kia Heimersson, Rula Zain, Robert Månsson, C I Edvard Smith, Marzia Palma. Hemasphere 2021
8
33

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.
Tjeerd Barf, Todd Covey, Raquel Izumi, Bas van de Kar, Michael Gulrajani, Bart van Lith, Maaike van Hoek, Edwin de Zwart, Diana Mittag, Dennis Demont,[...]. J Pharmacol Exp Ther 2017
186
33

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease.
Claire L Langrish, J Michael Bradshaw, Michelle R Francesco, Timothy D Owens, Yan Xing, Jin Shu, Jacob LaStant, Angelina Bisconte, Catherine Outerbridge, Stephen D White,[...]. J Immunol 2021
20
33

Characterization of all possible single-nucleotide change caused amino acid substitutions in the kinase domain of Bruton tyrosine kinase.
Jouni Väliaho, Imrul Faisal, Csaba Ortutay, C I Edvard Smith, Mauno Vihinen. Hum Mutat 2015
27
33

Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.
C I Smith, B Baskin, P Humire-Greiff, J N Zhou, P G Olsson, H S Maniar, P Kjellén, J D Lambris, B Christensson, L Hammarström. J Immunol 1994
230
33



Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Alessandro Gozzetti, Veronica Candi, Corrado Zuanelli Brambilla, Giulia Papini, Alberto Fabbri, Monica Bocchia. Anticancer Agents Med Chem 2017
2
50

Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
Melissa Hopper, Tarikere Gururaja, Taisei Kinoshita, James P Dean, Ronald J Hill, Ann Mongan. J Pharmacol Exp Ther 2020
9
33

The protein kinase complement of the human genome.
G Manning, D B Whyte, R Martinez, T Hunter, S Sudarsanam. Science 2002
33

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
John C Byrd, Bonnie Harrington, Susan O'Brien, Jeffrey A Jones, Anna Schuh, Steve Devereux, Jorge Chaves, William G Wierda, Farrukh T Awan, Jennifer R Brown,[...]. N Engl J Med 2016
583
33

The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species.
C I Smith, T C Islam, P T Mattsson, A J Mohamed, B F Nore, M Vihinen. Bioessays 2001
210
33

Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.
Shenqiu Wang, Sayan Mondal, Chunying Zhao, Marjan Berishaj, Phani Ghanakota, Connie Lee Batlevi, Ahmet Dogan, Venkatraman E Seshan, Robert Abel, Michael R Green,[...]. JCI Insight 2019
9
33

Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.
Douglas J Marcotte, Yu-Ting Liu, Robert M Arduini, Catherine A Hession, Konrad Miatkowski, Craig P Wildes, Patrick F Cullen, Victor Hong, Brian T Hopkins, Elisabeth Mertsching,[...]. Protein Sci 2010
100
33

Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib.
Alexander P Bye, Amanda J Unsworth, Michael J Desborough, Catherine A T Hildyard, Niamh Appleby, David Bruce, Neline Kriek, Sophie H Nock, Tanya Sage, Craig E Hughes,[...]. Blood Adv 2017
70
33

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Anthony R Mato, Nirav N Shah, Wojciech Jurczak, Chan Y Cheah, John M Pagel, Jennifer A Woyach, Bita Fakhri, Toby A Eyre, Nicole Lamanna, Manish R Patel,[...]. Lancet 2021
92
33

Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis.
Yan Lou, Xiaochun Han, Andreas Kuglstatter, Rama K Kondru, Zachary K Sweeney, Michael Soth, Joel McIntosh, Renee Litman, Judy Suh, Buelent Kocer,[...]. J Med Chem 2015
65
33

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.
Anne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, Loïc Ysebaert, Carole Fleury, Grégory Lazarian, Marie-Sarah Dilhuydy, Delphine Nollet, Romain Guieze, Pierre Feugier,[...]. Blood 2019
48
33


Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor.
Melissa F Adasme, Daniele Parisi, Kristien Van Belle, Sebastian Salentin, V Joachim Haupt, Gary S Jennings, Jörg-Christian Heinrich, Jean Herman, Ben Sprangers, Thierry Louat,[...]. PLoS One 2020
12
33


Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances.
Tingyu Wen, Jinsong Wang, Yuankai Shi, Haili Qian, Peng Liu. Leukemia 2021
58
33

Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.
Justin M Drake, John K Lee, Owen N Witte. Mol Cell Biol 2014
51
33


The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.
D Vetrie, I Vorechovský, P Sideras, J Holland, A Davies, F Flinter, L Hammarström, C Kinnon, R Levinsky, M Bobrow. Nature 1993
33

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
Zhengying Pan, Heleen Scheerens, Shyr-Jiann Li, Brian E Schultz, Paul A Sprengeler, L Chuck Burrill, Rohan V Mendonca, Michael D Sweeney, Keana C K Scott, Paul G Grothaus,[...]. ChemMedChem 2007
428
33

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
James J Crawford, Adam R Johnson, Dinah L Misner, Lisa D Belmont, Georgette Castanedo, Regina Choy, Melis Coraggio, Liming Dong, Charles Eigenbrot, Rebecca Erickson,[...]. J Med Chem 2018
107
33

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.
Kathleen M Gillooly, Claudine Pulicicchio, Mark A Pattoli, Lihong Cheng, Stacey Skala, Elizabeth M Heimrich, Kim W McIntyre, Tracy L Taylor, Daniel W Kukral, Shailesh Dudhgaonkar,[...]. PLoS One 2017
32
33

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents.
Joseph Maly, James S Blachly. Curr Hematol Malig Rep 2016
4
33

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate.
Qi Wang, Erik M Vogan, Laura M Nocka, Connor E Rosen, Julie A Zorn, Stephen C Harrison, John Kuriyan. Elife 2015
54
33

Conformation of full-length Bruton tyrosine kinase (Btk) from synchrotron X-ray solution scattering.
José A Márquez, C I Edvard Smith, Maxim V Petoukhov, Paola Lo Surdo, Pekka T Mattsson, Marika Knekt, Anna Westlund, Klaus Scheffzek, Matti Saraste, Dmitri I Svergun. EMBO J 2003
54
33

BTKbase: a database of XLA-causing mutations. International Study Group.
M Vihinen, M D Cooper, G de Saint Basile, A Fischer, R A Good, R W Hendriks, C Kinnon, S P Kwan, G W Litman, L D Notarangelo. Immunol Today 1995
72
33

Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
Andrew T Bender, Anna Gardberg, Albertina Pereira, Theresa Johnson, Yin Wu, Roland Grenningloh, Jared Head, Federica Morandi, Philipp Haselmayer, Lesley Liu-Bujalski. Mol Pharmacol 2017
55
33

Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.
Seungil Han, Robert M Czerwinski, Nicole L Caspers, David C Limburg, WeiDong Ding, Hong Wang, Jeffrey F Ohren, Francis Rajamohan, Thomas J McLellan, Ray Unwalla,[...]. Biochem J 2014
16
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.